E

Edwards Lifesciences

Develops transcatheter heart valves and devices

Senior Talent Management & Learning Specialist

Full-Time
No salary listed
Senior
Bachelor's
Limerick, Ireland
In Person
People & HRLearning & Development

About the job

Requirements
  • A Bachelor's Degree in Human Resources, Business, Psychology, Learning & Development, Organisational Development, or a related discipline.
  • A minimum of 5 years of progressive human resources experience, including experience in Talent Management, Learning & Development, Leadership Development, or Organisational Development.
  • Experience supporting manufacturing, medical device, pharmaceutical, life sciences, or highly regulated environments.
  • Demonstrated experience leading talent review, succession planning, learning strategy, and leadership development initiatives.
  • Experience influencing senior leaders and driving talent outcomes within a complex organisation.
  • Strong project management and change management experience.
  • Expertise in Talent Management, Succession Planning, Leadership Development, and Learning Governance.
  • Understanding of Irish employment legislation and learning compliance requirements.
  • Experience working with Workday Learning, Talent, Performance, and Succession modules.
  • Proven ability to use talent analytics and workforce data to influence business decisions.
  • Experience managing external learning providers and training partners.
  • Strong facilitation, presentation, and executive stakeholder management skills.
  • Demonstrated capability to operate independently while influencing across multiple levels of the organisation.
  • Excellent communication, coaching, and relationship-building skills.
  • A strategic mindset combined with a hands-on approach to execution in a manufacturing environment.
  • A strong continuous improvement orientation and ability to lead process optimisation initiatives.
  • A high level of professionalism, discretion, and ability to manage sensitive employee information.
Responsibilities
  • Lead annual talent review, succession planning, and organisational capability assessment processes for the Ireland site.
  • Partner with Plant Leadership and HR Business Partners to identify critical roles, succession risks, and talent pipeline requirements.
  • Facilitate calibration discussions and talent reviews to ensure consistent assessment of performance and potential across functions.
  • Develop and track talent action plans to accelerate readiness of key talent and strengthen succession bench strength.
  • Provide insights and recommendations based on talent analytics, workforce data, and organisational trends.
  • Own the site learning strategy and annual learning plan to support business priorities and workforce capability requirements.
  • Identify capability gaps and partner with business leaders to design and implement targeted development solutions.
  • Drive leadership development initiatives for frontline leaders, supervisors, managers, and functional leaders.
  • Ensure effective deployment of global learning programmes, leadership curricula, and development frameworks.
  • Evaluate learning effectiveness through metrics, learner feedback, business outcomes, and return-on-investment measures.
  • Support organisational effectiveness initiatives, change management programmes, and workforce transformation projects.
  • Drive employee development programmes, mentoring initiatives, career pathways, and internal mobility opportunities.
  • Promote a culture of continuous learning and professional development across the site.
  • Facilitate workshops, assessment centres, leadership programmes, and development interventions as required.
  • Act as a trusted advisor to Plant Leadership and people leaders on talent, leadership, learning, succession, and organisational effectiveness matters.
  • Collaborate with EMEA and Global Talent Management Centres of Excellence teams to ensure alignment with enterprise-wide initiatives.
  • Provide expert consultation on performance management, career development, leadership capability, and employee development planning.
  • Coach managers on talent identification, development planning, feedback, and performance conversations.
  • Own talent and learning data integrity within Workday Learning, Talent Management modules, and associated human resources systems.
  • Develop dashboards and reporting to monitor learning effectiveness, succession readiness, leadership pipeline health, and talent metrics.
  • Analyse workforce trends and provide actionable recommendations to improve capability and talent outcomes.
  • Lead continuous improvement initiatives to simplify processes, improve adoption, and enhance the employee experience.
  • Manage relationships with external learning providers and vendors, ensuring quality delivery and achievement of contractual service levels.
  • Serve as the senior escalation point for complex Talent Management and Learning issues.
  • Provide coaching, mentoring, and guidance to human resources colleagues and local stakeholders on Talent Management and Learning best practices.
  • Support the implementation of global human resources programmes while ensuring compliance with local employment practices and legislation.
  • Lead or participate in site, regional, and global human resources projects as required.

About the company

Edwards Lifesciences focuses on cardiovascular medical technologies, especially transcatheter heart valves. Its products enable repairing or replacing diseased heart valves through minimally invasive procedures rather than open-heart surgery. The company builds on a long history that began with the Starr-Edwards valve and now centers on valve therapies and related diagnostics to treat heart disease. It differentiates itself by specializing in valve technologies and transcatheter approaches, backed by a track record of clinical leadership and global reach. The goal is to improve patient outcomes by providing safer, less invasive valve treatment options for people around the world.

Company Size

10,001+

Company Stage

IPO

Headquarters

Irvine, California

Founded

1958

Get referred to Edwards Lifesciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CMS finalized expanded TAVR coverage September 10, 2026, enlarging addressable Medicare volume.
  • Q2 2026 sales rose 13.6% to $1.74 billion; management raised full-year guidance.
  • AUTUS approval and ECLIPTIS launch broaden growth beyond mature TAVR programs.

What critics are saying

  • FTC settled July 2026 JC Medical charges for $10 million and compliance oversight.
  • January 2026 injunction blocked JenaValve buyout, crippling Edwards' aortic-regurgitation acquisition strategy.
  • AtriaCure, Medtronic, and Boston Scientific attack Edwards' adjacencies; failure here destroys diversification.

What makes Edwards Lifesciences unique

  • Edwards owns SAPIEN TAVR leadership and the 2025 asymptomatic-label exclusivity.
  • AUTUS, approved October 1, 2026, creates a pediatric pulmonary-valve franchise.
  • ECLIPTIS, cleared July 2026, extends Edwards into surgical stroke-prevention during cardiac surgery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

10%

2 year growth

10%
Business Insider
Oct 2nd, 2026
Edwards Lifesciences (EW) receives a Buy from RBC Capital.

Edwards Lifesciences (EW) receives a Buy from RBC Capital. Oct. 2, 2026, 09:46 PM RBC Capital analyst Kendall Au maintained a Buy rating on Edwards Lifesciences on October 1 and set a price target of $110.00. The company's shares closed yesterday at $85.19. Au covers the Healthcare sector, focusing on stocks such as Becton Dickinson, GE Healthcare Technologies Inc, and Boston Scientific. According to TipRanks, Au has an average return of -3.6% and a 22.22% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Edwards Lifesciences with a $103.40 average price target, representing a 21.38% upside. In a report released on September 28, Leerink Partners also reiterated a Buy rating on the stock with a $101.00 price target. Based on Edwards Lifesciences' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.74 billion and a net profit of $241.9 million. In comparison, last year the company earned a revenue of $1.53 billion and had a net profit of $329.8 million Based on the recent corporate insider activity of 110 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Most recently, in August 2026, Annette Bruls, the CVP, EMEACLA of EW sold 2,644.00 shares for a total of $237,907.12. Read More on EW:

Business Wire
Oct 1st, 2026
Edwards Lifesciences wins FDA approval for AUTUS, first surgical pulmonary valve for pediatric patients

Edwards Lifesciences has received FDA approval for the AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed specifically for paediatric patients with congenital heart disease. The valve can be expanded as a child grows through a minimally invasive transcatheter procedure, potentially reducing the need for repeat open-heart surgeries. The approval was based on a pivotal study that met its primary safety and effectiveness endpoints. All patients were free from device-related complications through 30 days, with no valve reinterventions through six months. Patients who completed one-year follow-up showed consistent outcomes with favourable valve performance. The AUTUS valve previously received FDA Breakthrough Device designation for addressing an important unmet need in paediatric cardiac care.

Yahoo Finance
Sep 8th, 2026
Edwards Lifesciences beats Q2 expectations, raises 2026 guidance despite lagging Dow by 5.7%

Edwards Lifesciences, an Irvine, California-based cardiovascular products company, has underperformed the Dow Jones Industrial Average in recent months. The stock is down 6.6% from its 52-week high of $96.29 reached on 7 July. Over the past three months, Edwards Lifesciences shares grew 2.8%, lagging the Dow's 3.5% gain. The 52-week performance shows similar underperformance, with the stock up 11.4% compared to the Dow's 17.1% increase. Despite this, the company reported strong Q2 results on 23 July, with net sales rising 13.6% year-over-year to $1.7 billion. Adjusted earnings per share of $0.78 beat Wall Street estimates. The company raised its 2026 sales growth guidance to 10-11% from 9-11% previously. Analysts maintain a "strong buy" consensus rating, with a mean price target suggesting 13.5% upside potential.

BioPharma Watch
Sep 2nd, 2026
Edwards Lifesciences to present at the Deutsche Bank Healthcare Summit.

Edwards Lifesciences to present at the Deutsche Bank Healthcare Summit. Key Takeaway: Edwards Lifesciences Corporation will present at the Deutsche Bank Healthcare Summit on September 16, 2026. CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. A live webcast of the presentation will be available on their investor relations website. Market sentiment analysis. Positive factors. * Edwards Lifesciences is actively engaging with investors. * Participation in a prominent healthcare summit highlights company visibility. * CEO and CFO are presenting, indicating strong leadership presence. IRVINE, Calif.-(BUSINESS WIRE)-Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl Frequently asked questions. When will Edwards Lifesciences present at the summit? Edwards Lifesciences will present on September 16, 2026. Who will represent Edwards Lifesciences at the summit? CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. Is there a webcast available for the presentation? Yes, a live webcast will be available on their investor relations website.

DealLawyers.com
Aug 31st, 2026
Antitrust: KKR agrees to record settlement of HSR non-compliance claims.

Antitrust: KKR agrees to record settlement of HSR non-compliance claims. August 31, 2026 Last year, DealLawyers blogged about the DOJ's decision to file a lawsuit against KKR, in which it alleged that the buyout giant engaged in multiple failures to comply with the HSR Act's pre-merger notification requirements. Last week, the parties filed a proposed settlement of that lawsuit with the SDNY. This excerpt from a White & Case memo summarizes the terms of the settlement: On Wednesday, August 26, 2026, the DOJ filed a proposed settlement requiring KKR & Co. Inc. to pay a civil penalty of $250 million, more than 20 times any prior HSR penalty obtained by the DOJ. Associate Attorney General Stanley Woodward indicated that this proposed settlement "sends a powerful message" and shows that the DOJ "is committed to vigorous enforcement of the Act." This settlement comes after the DOJ alleged in January 2025 that the private equity sponsor "repeatedly violated the HSR Act" through "systemic" violations. Key allegations in the DOJ's complaint included: - Failure to submit responsive business documents required under Item 4 of the HSR Form - Altering or removing content and pages in final Item 4 documents before submission to the FTC/DOJ as part of required HSR filings - Failure to make HSR filings before consummating reportable transactions The memo quotes a KKR spokesperson as saying that the organization determined that continuing the litigation would be a distraction to the organization & that KKR was pleased to put the litigation behind it. They also noted that their investors wouldn't feel the bite, because KKR "will be fully reimbursed by outside law firms." Yikes!!! The settlement comes on the heels of last month's settlement of the FTC's actions targeting Edwards Lifesciences & Genesis Medtech's for alleged violations of the HSR Act. At the time, the $12 million fine that the companies agreed to pay was the largest ever for failing to make an HSR filing. I guess records were made to be broken. - John Jenkins